A phase II study of radioimmunotherapy with intraventricular 131I ‐3F8 for medulloblastoma

ConclusionscRIT with 131I‐3F8 is safe, has favorable dosimetry to CSF, and when added to salvage therapy using conventional modalities, may have clinical utility in maintaining remission in high‐risk or recurrent MB.

Source: Pediatric Blood and Cancer - September 22, 2017 Category: Cancer & Oncology Authors: Kim Kramer, Neeta Pandit ‐Taskar, John L. Humm, Pat B. Zanzonico, Sofia Haque, Ira J. Dunkel, Suzanne L. Wolden, Maria Donzelli, Debra A. Goldman, Jason S. Lewis, Serge K. Lyashchenko, Yasmin Khakoo, Jorge A. Carrasquillo, Mark M. Souweidane, Jeffrey P. Tags: RESEARCH ARTICLE Source Type: research